Napadano's revenue numbers for Lympro are indeed quite strange... i have seen many diagnostic companies starting with relatively low numbers for a new product....must of them however had the problem to get reimbursed....in the case of Lympro this is not the case for RUO...BP's either buy it or not....the challenge is of course to convince them to buy but i do believe thta the cost savings argument is a VERY STRONG ONE. so while i don't see revenues of 50 mln in 2015 i think a number between 10-30 mln is reasonable...in 2016 i would expect a number closer to 100 mln + since we will also get revenue under CLIA...in any case Napadano's numbers seem to be nonsense